RCM
GYRE icon

RA Capital Management’s Gyre Therapeutics GYRE Stock Holding History

RA Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-68,656
Closed -$13.3M – 28
2018
Q1 		$13.3M Buy
+68,656
New +$12.8M 1.02% 20

Other funds holding GYRE

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RA Capital Management's GYRE Position: Q2 2018 in Review

RA Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 68,656 shares — an estimated $13.3M sold.

RA Capital Management first reported a position in GYRE in Q1 2018 and held it in 1 quarter. The position peaked at $13.3M in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

  • RA Capital Management reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
  • RA Capital Management sold 68,656 Gyre Therapeutics shares in Q2 2018, an estimated $13.3M.
  • RA Capital Management first reported a position in Gyre Therapeutics in Q1 2018 and held it in 1 quarter.
  • RA Capital Management's Gyre Therapeutics position peaked at $13.3M in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on RA Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.